Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Income from Continuing Operations came in at 143227000.0 in Q2 2026, down 8.53% YoY from 156587749.75 in Q2 2025, and up 3.07% on a QoQ basis from 147758000.0 in Q1 2026.
Powered by 
Analysis
Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of Income from Continuing Operations data on file, last reported at 143227000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 8.53% year-over-year to 143227000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 502457000.0 (down 182.65% YoY) and the FY2025 annual result came in at 412781000.0, down 161.27% from the prior year.
- Income from Continuing Operations rose to 143227000.0 in Q2 2026, from 147758000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 947915000.0 in Q3 2024 to a low of 147758000.0 in Q1 2026.
- A 5-year average of 47739055.56 and a median of 98685000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 1137.97% — and 2025, when it sank 110.91%.
- Tracing AGIO's Income from Continuing Operations over 5 years: stood at 97109000.0 in 2022, then grew by 1.2% to 95940000.0 in 2023, then retreated by 0.61% to 96523000.0 in 2024, then dropped by 11.93% to 108039000.0 in 2025, then sank by 32.57% to 143227000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 143227000.0 (Q2 2026), 147758000.0 (Q1 2026), and 108039000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Agios Pharmaceuticals | 1.97 Bn | 1.97 Bn | 41.75 Mn | -100.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100.82 Mn |
| Mar 31, 2026 | -99.23 Mn |
| Dec 31, 2025 | -108.04 Mn |
| Sep 30, 2025 | -103.43 Mn |
| Jun 30, 2025 | -112.54 Mn |
| Mar 31, 2025 | -90.54 Mn |
| Dec 31, 2024 | -96.52 Mn |
| Sep 30, 2024 | 947.92 Mn |
| Jun 30, 2024 | -97.70 Mn |
| Mar 31, 2024 | -83.18 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -91.32 Mn |
| Jun 30, 2023 | -85.45 Mn |
| Mar 31, 2023 | -82.52 Mn |
| Dec 31, 2022 | -92.68 Mn |
| Sep 30, 2022 | -87.27 Mn |
| Jun 30, 2022 | -95.85 Mn |
| Mar 31, 2022 | -100.45 Mn |
| Dec 31, 2021 | -98.58 Mn |
| Sep 30, 2021 | -84.26 Mn |